Abstract
Methylmalonic acidemia (MMA), an inherited metabolic disorder caused by deficient activity of methylmalonyl-CoA mutase, carries a poor prognosis for long-term survival. While administration of a recombinant adeno-associated virus serotype 8 vector (rAAV8) can rescue Mut−/− mice from neonatal lethality and provide sustained phenotypic correction, translation of gene therapy to human subjects will likely require multiple rounds of systemic administration and, ideally, the use of a vector that transduces the kidney. To examine the effectiveness of alternative rAAVs in the treatment of MMA, a serotype 9 rAAV expressing the Mut cDNA was constructed and delivered to newborn Mut−/− mice (n=11). rAAV9 gene therapy directed hepatic transgene expression within 24 h and effectively rescued the Mut−/− mice from lethality, conferred long-term survival, markedly improved metabolism and resulted in striking preservation of renal function and histology. Systemic readministration of the vector at a dose similar to that used in human clinical trials (2.5 × 109 GC of rAAV9 per gram) to older, treated Mut−/− mice (n=5) lowered circulating metabolites, increased in vivo propionate oxidative capacity and produced transgene expression in the kidney and liver. Our data support the use of an rAAV9 vector in the acute and chronic treatment of MMA, and highlight the renal tropism afforded by this novel serotype.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fenton WA, Gravel RA, Rosenblatt DS . Disorders of propionate and methylmalonate metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Bases for Inhertited Disease, 8th edn. McGraw-Hill, Inc.: New York, 2001, pp 2165–2192.
Matsui SM, Mahoney MJ, Rosenberg LE . The natural history of the inherited methylmalonic acidemias. N Engl J Med 1983; 308: 857–861.
van der Meer SB, Poggi F, Spada M, Bonnefont JP, Ogier H, Hubert P et al. Clinical outcome of long-term management of patients with vitamin B12-unresponsive methylmalonic acidemia. J Pediatr 1994; 125 (Part 1): 903–908.
Nicolaides P, Leonard J, Surtees R . Neurological outcome of methylmalonic acidaemia. Arch Dis Child 1998; 78: 508–512.
de Baulny HO, Benoist JF, Rigal O, Touati G, Rabier D, Saudubray JM . Methylmalonic and propionic acidaemias: management and outcome. J Inherit Metab Dis 2005; 28: 415–423.
Horster F, Baumgartner MR, Viardot C, Suormala T, Burgard P, Fowler B et al. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut-, cblA, cblB). Pediatr Res 2007; 62: 225–230.
Cosson MA, Benoist JF, Touati G, Déchaux M, Royer N, Grandin L et al. Long-term outcome in methylmalonic aciduria: a series of 30 French patients. Mol Genet Metab 2009; 97: 172–178.
van ‘t Hoff WG, Dixon M, Taylor J, Mistry P, Rolles K, Rees L et al. Combined liver-kidney transplantation in methylmalonic acidemia. J Pediatr 1998; 132: 1043–1044.
Chakrapani A, Sivakumar P, McKiernan PJ, Leonard JV . Metabolic stroke in methylmalonic acidemia five years after liver transplantation. J Pediatr 2002; 140: 261–263.
Kayler LK, Merion RM, Lee S, Sung RS, Punch JD, Rudich SM et al. Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant 2002; 6: 295–300.
Nyhan WL, Gargus JJ, Boyle K, Selby R, Koch R . Progressive neurologic disability in methylmalonic acidemia despite transplantation of the liver. Eur J Pediatr 2002; 161: 377–379.
Hsui JY, Chien YH, Chu SY, Lu FL, Chen HL, Ho MJ et al. Living-related liver transplantation for methylmalonic acidemia: report of one case. Acta Paediatr Taiwan 2003; 44: 171–173.
Nagarajan S, Enns GM, Millan MT, Winter S, Sarwal MM . Management of methylmalonic acidaemia by combined liver-kidney transplantation. J Inherit Metab Dis 2005; 28: 517–524.
Kaplan P, Ficicioglu C, Mazur AT, Palmieri MJ, Berry GT . Liver transplantation is not curative for methylmalonic acidopathy caused by methylmalonyl-CoA mutase deficiency. Mol Genet Metab 2006; 88: 322–326.
Kasahara M, Horikawa R, Tagawa M, Uemoto S, Yokoyama S, Shibata Y et al. Current role of liver transplantation for methylmalonic acidemia: a review of the literature. Pediatr Transplant 2006; 10: 943–947.
Morioka D, Kasahara M, Horikawa R, Yokoyama S, Fukuda A, Nakagawa A . Efficacy of living donor liver transplantation for patients with methylmalonic acidemia. Am J Transplant 2007; 7: 2782–2787.
Mc Guire PJ, Lim-Melia E, Diaz GA, Raymond K, Larkin A, Wasserstein MP et al. Combined liver-kidney transplant for the management of methylmalonic aciduria: a case report and review of the literature. Mol Genet Metab 2008; 93: 22–29.
Oberholzer VG, Levin B, Burgess EA, Young WF . Methylmalonic aciduria. An inborn error of metabolism leading to chronic metabolic acidosis. Arch Dis Child 1967; 42: 492–504.
Walter JH, Michalski A, Wilson WM, Leonard JV, Barratt TM, Dillon MJ . Chronic renal failure in methylmalonic acidaemia. Eur J Pediatr 1989; 148: 344–348.
Van Calcar SC, Harding CO, Lyne P, Hogan K, Banerjee R, Sollinger H et al. Renal transplantation in a patient with methylmalonic acidaemia. J Inherit Metab Dis 1998; 21: 729–737.
Kolker S, Okun JG . Methylmalonic acid—an endogenous toxin? Cell Mol Life Sci 2005; 62: 621–624.
Chandler RJ, Venditti CP . Long-term rescue of a lethal murine model of methylmalonic acidemia using adeno-associated viral gene therapy. Mol Ther 2010; 18: 11–16.
Wu Z, Asokan A, Samulski RJ . Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316–327.
Gao G, Vandenberghe LH, Wilson JM . New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5: 285–297.
Schievenbusch S, Strack I, Scheffler M, Nischt R, Coutelle O, Hösel M et al. Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis. Mol Ther 2010; 18: 1302–1309.
Zincarelli C, Soltys S, Rengo G, Rabinowitz JE . Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16: 1073–1080.
Yue Y, Ghosh A, Long C, Bostick B, Smith BF, Kornegay JN et al. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 2008; 16: 1944–1952.
Yue Y, Shin JH, Duan D . Whole body skeletal muscle transduction in neonatal dogs with AAV-9. Methods Mol Biol 2011; 709: 313–329.
Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45–53.
Sarkar R, Mucci M, Addya S, Tetreault R, Bellinger DA, Nichols TC et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther 2006; 17: 427–439.
Prasad KM, Xu Y, Yang Z, Acton ST, French BA . Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther 2011; 18: 43–52.
Daly TM, Okuyama T, Vogler C, Haskins ME, Muzyczka N, Sands MS . Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum Gene Ther 1999; 10: 85–94.
Thomas CE, Storm TA, Huang Z, Kay MA . Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 2004; 78: 3110–3122.
Chandler RJ, Zerfas PM, Shanske S, Sloan J, Hoffmann V, DiMauro S et al. Mitochondrial dysfunction in mut methylmalonic acidemia. The FASEB J 2009; 23: 1252–1261.
Carrillo-Carrasco N, Chandler RJ, Chandrasekaran S, Venditti CP . Liver-directed recombinant adeno-associated viral gene delivery rescues a lethal mouse model of methylmalonic acidemia and provides long-term phenotypic correction. Hum Gene Ther 2010; 21: 1147–1154.
Limberis MP, Wilson JM . Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci USA 2006; 103: 12993–12998.
Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342–347.
Chandler RJ, Sloan J, Fu H, Tsai M, Stabler S, Allen R et al. Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscle. BMC Med Genet 2007; 8: 64.
Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM . Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854–11859.
Marcell PD, Stabler SP, Podell ER, Allen RH . Quantitation of methylmalonic acid and other dicarboxylic acids in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem 1985; 150: 58–66.
Allen RH, Stabler SP, Savage DG, Lindenbaum J . Elevation of 2-methylcitric acid I and II levels in serum, urine, and cerebrospinal fluid of patients with cobalamin deficiency. Metabolism 1993; 42: 978–988.
Barshop BA, Yoshida I, Ajami A, Sweetman L, Wolff JA, Sweetman FR et al. Metabolism of 1-13C-propionate in vivo in patients with disorders of propionate metabolism. Pediatr Res 1991; 30: 15–22.
Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004; 286: F590–F596.
Acknowledgements
JSS, RJC, JRS and CPV were supported, in part, by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. LL was supported, in part, by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. JRS also received support from the Angels for Alyssa MMA Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Gene Therapy website
Rights and permissions
About this article
Cite this article
Sénac, J., Chandler, R., Sysol, J. et al. Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery. Gene Ther 19, 385–391 (2012). https://doi.org/10.1038/gt.2011.108
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2011.108
Keywords
This article is cited by
-
Kidney-specific expression of GFP by in-utero delivery of pseudotyped adeno-associated virus 9
Molecular Therapy - Methods & Clinical Development (2014)
-
Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia
Orphanet Journal of Rare Diseases (2014)